References
  1. Chester W. Lipoidgranulomatose. Virchows Arch Pathol Anat 1930;279:561-602
  2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017
  3. Ahmed S, Bane A, Fozia Abdela DM, Kebede T. Erdheim-Chester Disease: A Rare Disease Causing Diagnostic Challenge in A 35 Year Old Male From Ethiopia. Journal of Cancer Research Reviews & Reports. SRC/JCRR-159. DOI: doi. org/10.47363/JCRR/2021 (3). 2021; 155.
  4. Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013; 72:1691
  5. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117:2783.
  6. Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017; 130:167
  7. Durham BH, Roos-Weil D, Baillou C, et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 2017; 130:176
  8. Dagna L, Girlanda S, Langheim S, Rizzo N, Bozzolo EP, Sabbadini MG, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford).2010;49:1203–6
  9. Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019;94(10):2054-2071
  10. Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 May;135(22):1929-1945
  11. Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357-366
  12. Ozkaya N, Rosenblum MK, Durham BH, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018;31(4):581-597
  13. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-2681
  14. Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis. 2015; 74(8):1596-1602.
  15. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54(12):4018-4022
  16. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):53-59
  17. Wilejto M, Abla O. Langerhans cell histiocytosis and Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):90-96
  18. Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, et al. Cardiovascular involvement, and overlooked feature of Erdheim-Chester disease. Report of 6 new cases and a literature review. Medicine 2004;83:371-92
  19. Haroche J, Cluzel P, Toledano D, Montalescot G, Touitou D, Grenier PA, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: Magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009;119:e597-8
  20. Serratrice J, Granel B, De Roux C, Pellissier JF, Swiader L, Bartoli JM, et al. Coated aorta: A new sign of Erdheim-Chester disease. J Rheumatol 2000;27:1550-53
  21. Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am. 2013;39(2):299-311
  22. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Jean-François E, et al. Erdheim-Chester disease. Curr Rheumatol Rep 2014;16:412
  23. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124:483–92
  24. Dion E, Graef C, Haroche J, et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol. 2004;183(5):1253-1260
  25. Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol. 2010;20(11):2579-2587
  26. Courtillot C, Laugier Robiolle S, Cohen Aubart F, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. J Clin Endocrinol Metab. 2016; 101(1):305-313
  27. Cives M, Simone V, Rizzo FM, et al. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015;95(1):1-11
  28. Sheu SY, Wenzel RR, Kersting C, Merten R, Otterbach F, Schmid KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004;57:1225–1228
  29. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.Blood. 2013;121(9):1495-1500
  30. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411-418
  31. Cohen-Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol. 2018;93(5):E114-E117
  32. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol. 2017;3(9):1253-1256
  33. Matzumura M, A SJ.r, Novak JE (2016) Erdheim-Chester disease: A rare presentation of a rare disease. J Investig Med High Impact Case Rep 4:1-4